Prevalence of human T-lymphotropic virus type I in patients with psoriasis and its effect on treatment choice: a multicenter observational study

Biologics have benefited psoriasis patients due to their high therapeutic efficacy. In 2019, the Japanese Dermatological Association has revised Guidance for the Use of Biologics in Psoriasis [1] for the safe use of biologics. It recommended screening tests for latent infections such as tuberculosis and viral hepatitis before starting the use of biologics. Human T-lymphotropic virus type I (HTLV-1) is a human retrovirus [2]. Some individuals with HTLV-1 infection develop adult T-cell leukemia-lymphoma (ATL) [3].

Source: Journal of Dermatological Science - May 12, 2023 Category: Dermatology Authors: Kentaro Yonekura, Noriko Tsuruta, Takuya Miyagi, Yuta Koike, Yuko Higashi, Takeshi Nakahara, Chika Ohata, Sakae Kaneko, Michiya Yamaguchi, Kanami Saito, Tetsuji Yanase, Shinichi Imafuku Source Type: research